董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David C. Greenberg | 男 | Director | 59 | 19.50万美元 | 未持股 | 2026-01-31 |
| Elisha W. Finney | 女 | Director | 64 | 未披露 | 未持股 | 2026-01-31 |
| Donald M. Abbey | 男 | Director | 59 | 未披露 | 未持股 | 2026-01-31 |
| Laurie Hernandez | 女 | Director | 68 | 未披露 | 未持股 | 2026-01-31 |
| David F. Hoffmeister | 男 | Director | 71 | 未披露 | 未持股 | 2026-01-31 |
| Vivek Jain | 男 | Chairman of the Board and Chief Executive Officer | 53 | 455.11万美元 | 未持股 | 2026-01-31 |
| Kolleen T. Kennedy | 女 | Director | 67 | 未披露 | 未持股 | 2026-01-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Virginia Sanzone | 女 | Corporate Vice President and General Counsel and Secretary | 51 | 未披露 | 未持股 | 2026-01-31 |
| Daniel Woolson | 男 | President | 49 | 未披露 | 未持股 | 2026-01-31 |
| Brian Bonnell | 男 | Chief Financial Officer and Treasurer | 52 | 未披露 | 未持股 | 2026-01-31 |
| Christian Voigtlander | 男 | Chief Operating Officer | 57 | 未披露 | 未持股 | 2026-01-31 |
| Vivek Jain | 男 | Chairman of the Board and Chief Executive Officer | 53 | 455.11万美元 | 未持股 | 2026-01-31 |
董事简历
中英对照 | 中文 | 英文- David C. Greenberg
-
David C. Greenberg，自2015年起担任董事，是审计委员会的成员。他自2008年6月起担任Medline Industries, Inc.（“Medline”）的战略执行副总裁，兼任Medline的执行委员会成员，并对公司各层领导提供咨询服务。他负责战略、业务开发和并购事务。此外，他也是集团总裁，负责Medline的分销业务和数个制造与营销部门。此前，他在Aon Corporation任职13年，担任过其子公司Aon Global的首席财务官等多个领导职位。他目前是Amendia, Inc.（脊柱植入公司）的董事。
David C. Greenberg has been a director since 2015, serves as Lead Independent Director and Chair of the Compensation Committee and is a member of the Audit Committee. Mr. Greenberg is currently serving as Chief Executive Officer of HomeThrive, Inc. Mr. Greenberg joined HomeThrive, Inc. in October 2018. Mr. Greenberg was Executive Vice President, Strategy of Medline Indtries, Inc. ("Medline") from June 2008 to October 2018. Medline is a privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care. In that capacity, Mr. Greenberg was a member of Medline's Executive Board and advised top leadership/ownership on all aspects of the biness. Mr. Greenberg was responsible for Strategy, Biness Development and M&A. Additionally, Mr. Greenberg was a Group President and had responsibility for Medline's distribution biness and several manufacturing and marketing divisions. Mr. Greenberg has served on the board of directors for Amendia, Inc., a spinal implant company. Previoly, Mr. Greenberg spent thirteen years in a variety of leadership positions within Aon Corporation, including Chief Financial Officer of its Aon Global subsidiary. Currently Mr. Greenberg serves on the board of directors of HomeThrive, Inc. since October 2018, Canadian Hospital Specialties, a privately held medical device manufacturer and specialty distributor, since April 2021 and Finnitiv Health (formerly Access & Integrated Practice Holdings, LLC), a comprehensive variable access medical services platform, since 2023. - David C. Greenberg，自2015年起担任董事，是审计委员会的成员。他自2008年6月起担任Medline Industries, Inc.（“Medline”）的战略执行副总裁，兼任Medline的执行委员会成员，并对公司各层领导提供咨询服务。他负责战略、业务开发和并购事务。此外，他也是集团总裁，负责Medline的分销业务和数个制造与营销部门。此前，他在Aon Corporation任职13年，担任过其子公司Aon Global的首席财务官等多个领导职位。他目前是Amendia, Inc.（脊柱植入公司）的董事。
- David C. Greenberg has been a director since 2015, serves as Lead Independent Director and Chair of the Compensation Committee and is a member of the Audit Committee. Mr. Greenberg is currently serving as Chief Executive Officer of HomeThrive, Inc. Mr. Greenberg joined HomeThrive, Inc. in October 2018. Mr. Greenberg was Executive Vice President, Strategy of Medline Indtries, Inc. ("Medline") from June 2008 to October 2018. Medline is a privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care. In that capacity, Mr. Greenberg was a member of Medline's Executive Board and advised top leadership/ownership on all aspects of the biness. Mr. Greenberg was responsible for Strategy, Biness Development and M&A. Additionally, Mr. Greenberg was a Group President and had responsibility for Medline's distribution biness and several manufacturing and marketing divisions. Mr. Greenberg has served on the board of directors for Amendia, Inc., a spinal implant company. Previoly, Mr. Greenberg spent thirteen years in a variety of leadership positions within Aon Corporation, including Chief Financial Officer of its Aon Global subsidiary. Currently Mr. Greenberg serves on the board of directors of HomeThrive, Inc. since October 2018, Canadian Hospital Specialties, a privately held medical device manufacturer and specialty distributor, since April 2021 and Finnitiv Health (formerly Access & Integrated Practice Holdings, LLC), a comprehensive variable access medical services platform, since 2023.
- Elisha W. Finney
-
Elisha W. Finney，自2017年11月起担任董事。她担任审计委员会主席。她拥有乔治亚大学风险管理和保险工商管理学士学位，金门大学工商管理硕士学位。Finney是NanoString Technologies，Inc.的董事和审计委员会主席，以及ICU Medical, Inc.和Viatris Inc.的董事，她是这两家公司的审计委员会成员。她此前曾担任Cutera，Inc.的董事至2019年6月，Irobot Corporation至2021年11月。Finney女士自1999年至2017年6月退休期间一直担任Varian医疗 Inc.的首席财务官。她于1988年加入Varian，在被任命为首席财务官之前曾担任过多种财务职务。
Elisha W. Finney has been a director since January 2016, and serves as Chair of the Nominating and Governance Committee and is a member of the Audit Committee. Ms. Finney, now retired, was named Vice President, Finance and CFO of Varian Medical Systems in April 1999. In January 2005, she was promoted to Senior Vice President and given additional management responsibility for the Corporate Information Systems group. She was named Executive Vice President in February 2012. Varian Medical Systems is a leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. Ms. Finney managed a worldwide staff of 400. Her management responsibilities included corporate accounting; corporate communications and investor relations; internal financial and compliance audit; risk management; tax and treasury, and corporate information systems. Ms. Finney joined Varian as risk manager in 1988 and has assumed a wide variety of finance functions over her last 29 years with the company. Prior to joining Varian, Ms. Finney was with the Fox Group in Foster City, CA, and Beatrice Foods, a major food processing company, in Chicago, IL. Ms. Finney has served on the boards of: Mettler Toledo, a multinational manufacturer of scales and analytical instruments, since November 2017; and Viatris, a global pharmaceutical and healthcare corporation, since December 2022. Ms. Finney previoly served on the boards of directors of: Nanostring Technologies from May 2017 to June 2024; Laserscope from Augt 2005 until July 2006 when Laserscope was sold to American Medical Systems; Thoratec, a developer, manufacturer and marketer of proprietary medical devices for mechanical circulatory support from July 2007 to May 2013; Altera Corporation, a manufacturer of programmable logic devices from September 2011 until December 2015, when Altera was sold to Intel; Cutera, Inc. a global provider of laser and other energy based aesthetic systems, from November 2017 to May 2019; and iRobot Corporation, a robotics technology company, from January 2017 to November 2021. - Elisha W. Finney，自2017年11月起担任董事。她担任审计委员会主席。她拥有乔治亚大学风险管理和保险工商管理学士学位，金门大学工商管理硕士学位。Finney是NanoString Technologies，Inc.的董事和审计委员会主席，以及ICU Medical, Inc.和Viatris Inc.的董事，她是这两家公司的审计委员会成员。她此前曾担任Cutera，Inc.的董事至2019年6月，Irobot Corporation至2021年11月。Finney女士自1999年至2017年6月退休期间一直担任Varian医疗 Inc.的首席财务官。她于1988年加入Varian，在被任命为首席财务官之前曾担任过多种财务职务。
- Elisha W. Finney has been a director since January 2016, and serves as Chair of the Nominating and Governance Committee and is a member of the Audit Committee. Ms. Finney, now retired, was named Vice President, Finance and CFO of Varian Medical Systems in April 1999. In January 2005, she was promoted to Senior Vice President and given additional management responsibility for the Corporate Information Systems group. She was named Executive Vice President in February 2012. Varian Medical Systems is a leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. Ms. Finney managed a worldwide staff of 400. Her management responsibilities included corporate accounting; corporate communications and investor relations; internal financial and compliance audit; risk management; tax and treasury, and corporate information systems. Ms. Finney joined Varian as risk manager in 1988 and has assumed a wide variety of finance functions over her last 29 years with the company. Prior to joining Varian, Ms. Finney was with the Fox Group in Foster City, CA, and Beatrice Foods, a major food processing company, in Chicago, IL. Ms. Finney has served on the boards of: Mettler Toledo, a multinational manufacturer of scales and analytical instruments, since November 2017; and Viatris, a global pharmaceutical and healthcare corporation, since December 2022. Ms. Finney previoly served on the boards of directors of: Nanostring Technologies from May 2017 to June 2024; Laserscope from Augt 2005 until July 2006 when Laserscope was sold to American Medical Systems; Thoratec, a developer, manufacturer and marketer of proprietary medical devices for mechanical circulatory support from July 2007 to May 2013; Altera Corporation, a manufacturer of programmable logic devices from September 2011 until December 2015, when Altera was sold to Intel; Cutera, Inc. a global provider of laser and other energy based aesthetic systems, from November 2017 to May 2019; and iRobot Corporation, a robotics technology company, from January 2017 to November 2021.
- Donald M. Abbey
-
Donald M. Abbey自2017年1月起担任Dexcom, Inc.的全球商业服务，IT，质量和监管事务执行副总裁，并于2016年5月至2017年1月担任Dexcom, Inc.的质量执行副总裁。2007年3月至2016年4月，Abbey先生担任2015年3月CareFusion的收购方Becton Dickinson的执行职务，CareFusion本身于2009年从Cardinal Health剥离出来，包括2015年3月至2016年5月担任Becton Dickinson的质量和监管高级副总裁，2011年5月至2015年3月，担任Carefusion的质量，监管和医疗事务执行副总裁，2009年10月至2011年5月，担任Carefusion的质量和监管高级副总裁，2007年3月至2009年10月，担任Cardinal Health的质量和监管高级副总裁。2007年之前，Abbey先生在Respironics，Welch Allyn和Philips医疗保健担任高级质量和监管事务以及一般管理职位。Abbey先生在瓦里安医疗公司（Varian Medical）和波士顿科学公司（Boston Scientific）开始了他的职业生涯，在研究与开发和质量方面的责任越来越大。Abbey先生获得了华盛顿州立大学的学士学位和华盛顿大学的MBA学位。
Donald M. Abbey has served as our Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs since January 2017 and served as our Executive Vice President, Quality from May 2016 to January 2017. From March 2007 to April 2016 Mr. Abbey served in executive roles for Becton Dickinson the acquirer of CareFusion in March 2015 which itself was spun off from Cardinal Health in 2009 including as Senior Vice President, Quality and Regulatory for Becton Dickinson from March 2015 to May 2016 as Executive Vice President, Quality, Regulatory and Medical Affairs for CareFusion from May 2011 to March 2015 as Senior Vice President, Quality and Regulatory for CareFusion from October 2009 to May 2011 and as Senior Vice President, Quality and Regulatory for Cardinal Health from March 2007 to October 2009. Prior to 2007 Mr. Abbey held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn, and Philips Healthcare. Mr. Abbey began his career at Varian Medical and Boston Scientific holding positions of increasing responsibility in research and development and quality. Mr. Abbey received a B.S.E.E. from Washington State University and an MBA from the University of Washington. - Donald M. Abbey自2017年1月起担任Dexcom, Inc.的全球商业服务，IT，质量和监管事务执行副总裁，并于2016年5月至2017年1月担任Dexcom, Inc.的质量执行副总裁。2007年3月至2016年4月，Abbey先生担任2015年3月CareFusion的收购方Becton Dickinson的执行职务，CareFusion本身于2009年从Cardinal Health剥离出来，包括2015年3月至2016年5月担任Becton Dickinson的质量和监管高级副总裁，2011年5月至2015年3月，担任Carefusion的质量，监管和医疗事务执行副总裁，2009年10月至2011年5月，担任Carefusion的质量和监管高级副总裁，2007年3月至2009年10月，担任Cardinal Health的质量和监管高级副总裁。2007年之前，Abbey先生在Respironics，Welch Allyn和Philips医疗保健担任高级质量和监管事务以及一般管理职位。Abbey先生在瓦里安医疗公司（Varian Medical）和波士顿科学公司（Boston Scientific）开始了他的职业生涯，在研究与开发和质量方面的责任越来越大。Abbey先生获得了华盛顿州立大学的学士学位和华盛顿大学的MBA学位。
- Donald M. Abbey has served as our Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs since January 2017 and served as our Executive Vice President, Quality from May 2016 to January 2017. From March 2007 to April 2016 Mr. Abbey served in executive roles for Becton Dickinson the acquirer of CareFusion in March 2015 which itself was spun off from Cardinal Health in 2009 including as Senior Vice President, Quality and Regulatory for Becton Dickinson from March 2015 to May 2016 as Executive Vice President, Quality, Regulatory and Medical Affairs for CareFusion from May 2011 to March 2015 as Senior Vice President, Quality and Regulatory for CareFusion from October 2009 to May 2011 and as Senior Vice President, Quality and Regulatory for Cardinal Health from March 2007 to October 2009. Prior to 2007 Mr. Abbey held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn, and Philips Healthcare. Mr. Abbey began his career at Varian Medical and Boston Scientific holding positions of increasing responsibility in research and development and quality. Mr. Abbey received a B.S.E.E. from Washington State University and an MBA from the University of Washington.
- Laurie Hernandez
-
Laurie Hernandez自2021年7月起担任董事，是提名和治理委员会的成员。Hernandez女士是一位退休的医疗保健高管，拥有超过25年的战略性医疗保健经验。Hernandez女士于2007年11月加入Baxter Healthcare Corporation（“Baxter”），在该公司工作的10年中担任了各种各样的战略职位。在加入Baxter之前，Hernandez女士在伊利诺伊州Lake Forest的Hospira Inc.工作。Hernandez Previoly女士曾在伊利诺伊州芝加哥的西奈卫生系统和伊利诺伊州利伯蒂维尔的羔羊农场担任董事会成员。
Laurie Hernandez has been a director since July 2021 and is a member of the Nominating and Governance Committee. Ms. Hernandez is a retired healthcare executive with over 25 years of strategic healthcare experience. Ms. Hernandez joined Baxter Healthcare Corporation ("Baxter") in November of 2007 and has assumed a wide variety of strategic positions over her 10 years with that company. Prior to joining Baxter, Ms. Hernandez was with Hospira Inc. in Lake Forest, Illinois. Ms. Hernandez previoly served on the boards of Sinai Health System in Chicago, Illinois and Lambs Farm in Libertyville, Illinois. - Laurie Hernandez自2021年7月起担任董事，是提名和治理委员会的成员。Hernandez女士是一位退休的医疗保健高管，拥有超过25年的战略性医疗保健经验。Hernandez女士于2007年11月加入Baxter Healthcare Corporation（“Baxter”），在该公司工作的10年中担任了各种各样的战略职位。在加入Baxter之前，Hernandez女士在伊利诺伊州Lake Forest的Hospira Inc.工作。Hernandez Previoly女士曾在伊利诺伊州芝加哥的西奈卫生系统和伊利诺伊州利伯蒂维尔的羔羊农场担任董事会成员。
- Laurie Hernandez has been a director since July 2021 and is a member of the Nominating and Governance Committee. Ms. Hernandez is a retired healthcare executive with over 25 years of strategic healthcare experience. Ms. Hernandez joined Baxter Healthcare Corporation ("Baxter") in November of 2007 and has assumed a wide variety of strategic positions over her 10 years with that company. Prior to joining Baxter, Ms. Hernandez was with Hospira Inc. in Lake Forest, Illinois. Ms. Hernandez previoly served on the boards of Sinai Health System in Chicago, Illinois and Lambs Farm in Libertyville, Illinois.
- David F. Hoffmeister
-
David F. Hoffmeister，Life Technologies Corporation的高级副总裁兼首席财务官，在ThermoFisher Scientific Inc.收购Life Technologies Corporation之前（2008 – 2014年）。生物技术公司Invitrogen Corporation的首席财务官，Invitrogen Corporation与Applied Biosystems合并成立生命技术公司（2004 – 2008）。McKinsey & Company高级合伙人，就战略问题为医疗保健、私人股本和化工行业的客户提供服务（1984 – 2004），包括担任McKinsey & Company北美化工业务负责人（1998 – 2004）。
David F. Hoffmeister,served as the Senior Vice President and Chief Financial Officer of Life Technologies Corporation, a global life sciences company, from 2008 to 2014 when it was acquired by Thermo Fisher Scientific Inc. From 2004 to 2008, he served as Chief Financial Officer of Invitrogen Corporation, which merged with Applied Biosystems in 2008 to form Life Technologies Corporation. Prior to joining Invitrogen, Mr. Hoffmeister spent 20 years with McKinsey & Company as a senior partner serving clients in the healthcare, private equity and chemical industries on issues of strategy and organization. Before joining McKinsey & Company, he held financial positions at GTE Corp. and W.R. Grace and Co. Mr. Hoffmeister currently serves on the boards of directors of Celanese Corporation (since 2006), Glaukos Corporation (since 2014) and ICU Medical, Inc. (since 2018). He also serves on the board of directors of Kaiser Foundation Hospitals and Kaiser Foundation Health Plan, Inc. (since 2014). Mr. Hoffmeister received his BS from the University of Minnesota and his MBA from the University of Chicago. - David F. Hoffmeister，Life Technologies Corporation的高级副总裁兼首席财务官，在ThermoFisher Scientific Inc.收购Life Technologies Corporation之前（2008 – 2014年）。生物技术公司Invitrogen Corporation的首席财务官，Invitrogen Corporation与Applied Biosystems合并成立生命技术公司（2004 – 2008）。McKinsey & Company高级合伙人，就战略问题为医疗保健、私人股本和化工行业的客户提供服务（1984 – 2004），包括担任McKinsey & Company北美化工业务负责人（1998 – 2004）。
- David F. Hoffmeister,served as the Senior Vice President and Chief Financial Officer of Life Technologies Corporation, a global life sciences company, from 2008 to 2014 when it was acquired by Thermo Fisher Scientific Inc. From 2004 to 2008, he served as Chief Financial Officer of Invitrogen Corporation, which merged with Applied Biosystems in 2008 to form Life Technologies Corporation. Prior to joining Invitrogen, Mr. Hoffmeister spent 20 years with McKinsey & Company as a senior partner serving clients in the healthcare, private equity and chemical industries on issues of strategy and organization. Before joining McKinsey & Company, he held financial positions at GTE Corp. and W.R. Grace and Co. Mr. Hoffmeister currently serves on the boards of directors of Celanese Corporation (since 2006), Glaukos Corporation (since 2014) and ICU Medical, Inc. (since 2018). He also serves on the board of directors of Kaiser Foundation Hospitals and Kaiser Foundation Health Plan, Inc. (since 2014). Mr. Hoffmeister received his BS from the University of Minnesota and his MBA from the University of Chicago.
- Vivek Jain
-
Vivek Jain，曾担任Analog Devices， Inc.自2022年5月以来，他担任全球运营和技术执行副总裁，负责全球制造和供应链运营，此前曾担任Analog Devices， Inc.。从2021年8月到2022年5月，担任全球运营和技术高级副总裁。在Analog Devices， Inc.收购Maxim之后，他担任该职位，从2009年6月到2021年8月担任技术和制造集团高级副总裁。在2007年加入Maxim担任Fab Operations副总裁后，Jain先生领导了Maxim制造供应链的许多方面的转型，使其更加灵活，敏捷和有弹性。Jain先生的其他经验包括担任英特尔技术开发和制造工厂的工厂经理，在那里他监督深亚微米逻辑和闪存技术的工艺技术开发和大批量制造。他持有the Indian Institute of Technology Delhi的化学工程学士学位，宾夕法尼亚州立大学（Penn State University）的化学工程硕士学位，以及斯坦福大学（Stanford University）的电气工程硕士学位。
Vivek Jain joined the Company in February 2014 as Chairman of the Board and Chief Executive Officer. Mr. Jain served as CareFion Corporation's ("CareFion") President of Procedural Solutions from 2011 to February 2014. Mr. Jain served as President, Medical Technologies and Services of CareFion from 2009 until 2011. Mr. Jain served as the Executive Vice President Strategy and Corporate Development of Cardinal Health from 2007 until 2009. Mr. Jain served as Senior Vice President, Biness Development and M&A for the Philips Medical Systems biness of Koninklijke Philips Electronics N.V., an electronics company from 2006 to Augt 2007. Mr. Jain served as an investment banker at J.P. Morgan Securities, Inc., an investment banking firm, from 1994 to 2006. Mr. Jain's last position with J.P. Morgan was as Co Head of Global Healthcare Investment Banking from 2002 to 2006. - Vivek Jain，曾担任Analog Devices， Inc.自2022年5月以来，他担任全球运营和技术执行副总裁，负责全球制造和供应链运营，此前曾担任Analog Devices， Inc.。从2021年8月到2022年5月，担任全球运营和技术高级副总裁。在Analog Devices， Inc.收购Maxim之后，他担任该职位，从2009年6月到2021年8月担任技术和制造集团高级副总裁。在2007年加入Maxim担任Fab Operations副总裁后，Jain先生领导了Maxim制造供应链的许多方面的转型，使其更加灵活，敏捷和有弹性。Jain先生的其他经验包括担任英特尔技术开发和制造工厂的工厂经理，在那里他监督深亚微米逻辑和闪存技术的工艺技术开发和大批量制造。他持有the Indian Institute of Technology Delhi的化学工程学士学位，宾夕法尼亚州立大学（Penn State University）的化学工程硕士学位，以及斯坦福大学（Stanford University）的电气工程硕士学位。
- Vivek Jain joined the Company in February 2014 as Chairman of the Board and Chief Executive Officer. Mr. Jain served as CareFion Corporation's ("CareFion") President of Procedural Solutions from 2011 to February 2014. Mr. Jain served as President, Medical Technologies and Services of CareFion from 2009 until 2011. Mr. Jain served as the Executive Vice President Strategy and Corporate Development of Cardinal Health from 2007 until 2009. Mr. Jain served as Senior Vice President, Biness Development and M&A for the Philips Medical Systems biness of Koninklijke Philips Electronics N.V., an electronics company from 2006 to Augt 2007. Mr. Jain served as an investment banker at J.P. Morgan Securities, Inc., an investment banking firm, from 1994 to 2006. Mr. Jain's last position with J.P. Morgan was as Co Head of Global Healthcare Investment Banking from 2002 to 2006.
- Kolleen T. Kennedy
-
Kolleen T. Kennedy被任命为负责肿瘤系统的高级副总裁及总裁，2011年10月起生效。从2006年1月至2011年9月担任负责肿瘤系统客户服务和支持的副总裁。在此之前，从2004年9月至2006年1月担任公司负责肿瘤系统市场营销、产品管理和工程的副总裁。自1997年加入公司到成为副总裁之前，曾担任多个营销管理职位。在韦恩州立大学获得放射肿瘤学学士学位和心理学学士学位，在科罗拉多大学获得医学物理硕士学位。
Kolleen T. Kennedy was appointed President of Proton Solutions and Chief Growth Officer effective October 2018. Ms. Kennedy served as Executive Vice President and President, Oncology Systems from September 2014 to September 2018 and was Senior Vice President and President, Oncology Systems from October 2011 to September 2014. From January 2006 through September 2011 Ms. Kennedy served as Vice President, Oncology Systems Customer Service and Support. Prior to that, Ms. Kennedy was the Company’s Vice President, Oncology Systems Marketing, Product Management and Engineering from September 2004 to January 2006. Prior to becoming Vice President, Ms. Kennedy served in various marketing management positions since she joined the Company in 1997. Ms. Kennedy holds a B.S. degree in Radiation Oncology and a B.S. degree in Psychology, both from Wayne State University, as well as an M.S. degree in Medical Physics from the University of Colorado. - Kolleen T. Kennedy被任命为负责肿瘤系统的高级副总裁及总裁，2011年10月起生效。从2006年1月至2011年9月担任负责肿瘤系统客户服务和支持的副总裁。在此之前，从2004年9月至2006年1月担任公司负责肿瘤系统市场营销、产品管理和工程的副总裁。自1997年加入公司到成为副总裁之前，曾担任多个营销管理职位。在韦恩州立大学获得放射肿瘤学学士学位和心理学学士学位，在科罗拉多大学获得医学物理硕士学位。
- Kolleen T. Kennedy was appointed President of Proton Solutions and Chief Growth Officer effective October 2018. Ms. Kennedy served as Executive Vice President and President, Oncology Systems from September 2014 to September 2018 and was Senior Vice President and President, Oncology Systems from October 2011 to September 2014. From January 2006 through September 2011 Ms. Kennedy served as Vice President, Oncology Systems Customer Service and Support. Prior to that, Ms. Kennedy was the Company’s Vice President, Oncology Systems Marketing, Product Management and Engineering from September 2004 to January 2006. Prior to becoming Vice President, Ms. Kennedy served in various marketing management positions since she joined the Company in 1997. Ms. Kennedy holds a B.S. degree in Radiation Oncology and a B.S. degree in Psychology, both from Wayne State University, as well as an M.S. degree in Medical Physics from the University of Colorado.
高管简历
中英对照 | 中文 | 英文- Virginia Sanzone
Virginia Sanzone自2018年1月起担任公司副总裁、总法律顾问和秘书。Sanzone女士还担任合规官。Sanzone女士于2015年8月至2018年1月担任公司副总裁兼总法律顾问。在2015年8月之前，Sanzone女士在CareFion担任过多个职务，最后担任高级副总裁、副总法律顾问Biness Segments & Americas。
Virginia Sanzone has served as Corporate Vice President, General Counsel and Secretary since January 2018. Ms. Sanzone also serves as Compliance Officer. Ms. Sanzone served as the Company's Vice President, General Counsel from Augt of 2015 to January 2018. Prior to Augt of 2015, Ms. Sanzone held vario roles at CareFion and last served as Senior Vice President, Associate General Counsel Biness Segments & Americas.- Virginia Sanzone自2018年1月起担任公司副总裁、总法律顾问和秘书。Sanzone女士还担任合规官。Sanzone女士于2015年8月至2018年1月担任公司副总裁兼总法律顾问。在2015年8月之前，Sanzone女士在CareFion担任过多个职务，最后担任高级副总裁、副总法律顾问Biness Segments & Americas。
- Virginia Sanzone has served as Corporate Vice President, General Counsel and Secretary since January 2018. Ms. Sanzone also serves as Compliance Officer. Ms. Sanzone served as the Company's Vice President, General Counsel from Augt of 2015 to January 2018. Prior to Augt of 2015, Ms. Sanzone held vario roles at CareFion and last served as Senior Vice President, Associate General Counsel Biness Segments & Americas.
- Daniel Woolson
丹尼尔·伍尔森自2024年10月起担任总统。在成为总裁之前，Woolson先生曾于2017年1月至2024年10月担任公司副总裁兼Infion Systems总经理。Woolson先生于2015年3月至2016年11月担任Becton Dickinson呼吸解决方案总裁。在2015年3月之前，Woolson先生在CareFion担任过多个职务，最后担任过Specialty Disposables副总裁/总经理。
Daniel Woolson has served as President since October 2024. Prior to becoming President, Mr. Woolson served as Corporate Vice President, General Manager Infion Systems from January 2017 to October 2024. Mr. Woolson served as President, Respiratory Solutions for Becton Dickinson from March 2015 to November 2016. Prior to March 2015, Mr. Woolson held vario roles at CareFion and last served as Vice President/General Manager, Specialty Disposables.- 丹尼尔·伍尔森自2024年10月起担任总统。在成为总裁之前，Woolson先生曾于2017年1月至2024年10月担任公司副总裁兼Infion Systems总经理。Woolson先生于2015年3月至2016年11月担任Becton Dickinson呼吸解决方案总裁。在2015年3月之前，Woolson先生在CareFion担任过多个职务，最后担任过Specialty Disposables副总裁/总经理。
- Daniel Woolson has served as President since October 2024. Prior to becoming President, Mr. Woolson served as Corporate Vice President, General Manager Infion Systems from January 2017 to October 2024. Mr. Woolson served as President, Respiratory Solutions for Becton Dickinson from March 2015 to November 2016. Prior to March 2015, Mr. Woolson held vario roles at CareFion and last served as Vice President/General Manager, Specialty Disposables.
- Brian Bonnell
Brian Bonnell自2020年3月3日起担任首席财务官兼财务主管。自2018年5月至2020年3月，Bonnell先生担任公司财务副总裁。在加入公司之前，Bonnell先生曾于2015年5月至2017年12月期间在Alere Inc.担任财务主管兼财务规划和分析主管。在2015年5月之前，Bonnell先生曾在CareFion Corporation担任多个财务职务，最后担任高级副总裁、税务和财务主管。
Brian Bonnell has served as Chief Financial Officer and Treasurer since March 3, 2020. From May 2018 until March 2020, Mr. Bonnell served as the Company's Corporate Vice President, Finance. Prior to joining the Company, Mr. Bonnell served as Treasurer and Head of Financial Planning and Analysis at Alere Inc. from May 2015 until December 2017. Prior to May 2015, Mr. Bonnell held vario roles at CareFion Corporation in Finance and last served as Senior Vice President, Tax and Treasurer.- Brian Bonnell自2020年3月3日起担任首席财务官兼财务主管。自2018年5月至2020年3月，Bonnell先生担任公司财务副总裁。在加入公司之前，Bonnell先生曾于2015年5月至2017年12月期间在Alere Inc.担任财务主管兼财务规划和分析主管。在2015年5月之前，Bonnell先生曾在CareFion Corporation担任多个财务职务，最后担任高级副总裁、税务和财务主管。
- Brian Bonnell has served as Chief Financial Officer and Treasurer since March 3, 2020. From May 2018 until March 2020, Mr. Bonnell served as the Company's Corporate Vice President, Finance. Prior to joining the Company, Mr. Bonnell served as Treasurer and Head of Financial Planning and Analysis at Alere Inc. from May 2015 until December 2017. Prior to May 2015, Mr. Bonnell held vario roles at CareFion Corporation in Finance and last served as Senior Vice President, Tax and Treasurer.
- Christian Voigtlander
Christian Voigtlander自2018年1月起担任首席运营官。2017年2月至2018年1月，Voigtlander先生担任公司BINEY Development公司副总裁兼Infion Solutions公司总经理。2015年6月至2017年2月，Voigtlander先生担任公司副总裁，BINEY Development。在2015年5月之前，Voigtlander先生曾在CareFion担任过多个职务，最后一次担任Biness发展和战略高级副总裁。
Christian Voigtlander has served as Chief Operating Officer since January 2018. From February 2017 to January 2018, Mr. Voigtlander served as the Company's Corporate Vice President, Biness Development and General Manager, Infion Solutions. From June 2015 to February 2017, Mr. Voigtlander served as the Company's Vice President, Biness Development. Prior to May 2015, Mr. Voigtlander held vario roles at CareFion and last served as Senior Vice President, Biness Development and Strategy.- Christian Voigtlander自2018年1月起担任首席运营官。2017年2月至2018年1月，Voigtlander先生担任公司BINEY Development公司副总裁兼Infion Solutions公司总经理。2015年6月至2017年2月，Voigtlander先生担任公司副总裁，BINEY Development。在2015年5月之前，Voigtlander先生曾在CareFion担任过多个职务，最后一次担任Biness发展和战略高级副总裁。
- Christian Voigtlander has served as Chief Operating Officer since January 2018. From February 2017 to January 2018, Mr. Voigtlander served as the Company's Corporate Vice President, Biness Development and General Manager, Infion Solutions. From June 2015 to February 2017, Mr. Voigtlander served as the Company's Vice President, Biness Development. Prior to May 2015, Mr. Voigtlander held vario roles at CareFion and last served as Senior Vice President, Biness Development and Strategy.
- Vivek Jain
Vivek Jain，曾担任Analog Devices， Inc.自2022年5月以来，他担任全球运营和技术执行副总裁，负责全球制造和供应链运营，此前曾担任Analog Devices， Inc.。从2021年8月到2022年5月，担任全球运营和技术高级副总裁。在Analog Devices， Inc.收购Maxim之后，他担任该职位，从2009年6月到2021年8月担任技术和制造集团高级副总裁。在2007年加入Maxim担任Fab Operations副总裁后，Jain先生领导了Maxim制造供应链的许多方面的转型，使其更加灵活，敏捷和有弹性。Jain先生的其他经验包括担任英特尔技术开发和制造工厂的工厂经理，在那里他监督深亚微米逻辑和闪存技术的工艺技术开发和大批量制造。他持有the Indian Institute of Technology Delhi的化学工程学士学位，宾夕法尼亚州立大学（Penn State University）的化学工程硕士学位，以及斯坦福大学（Stanford University）的电气工程硕士学位。
Vivek Jain joined the Company in February 2014 as Chairman of the Board and Chief Executive Officer. Mr. Jain served as CareFion Corporation's ("CareFion") President of Procedural Solutions from 2011 to February 2014. Mr. Jain served as President, Medical Technologies and Services of CareFion from 2009 until 2011. Mr. Jain served as the Executive Vice President Strategy and Corporate Development of Cardinal Health from 2007 until 2009. Mr. Jain served as Senior Vice President, Biness Development and M&A for the Philips Medical Systems biness of Koninklijke Philips Electronics N.V., an electronics company from 2006 to Augt 2007. Mr. Jain served as an investment banker at J.P. Morgan Securities, Inc., an investment banking firm, from 1994 to 2006. Mr. Jain's last position with J.P. Morgan was as Co Head of Global Healthcare Investment Banking from 2002 to 2006.- Vivek Jain，曾担任Analog Devices， Inc.自2022年5月以来，他担任全球运营和技术执行副总裁，负责全球制造和供应链运营，此前曾担任Analog Devices， Inc.。从2021年8月到2022年5月，担任全球运营和技术高级副总裁。在Analog Devices， Inc.收购Maxim之后，他担任该职位，从2009年6月到2021年8月担任技术和制造集团高级副总裁。在2007年加入Maxim担任Fab Operations副总裁后，Jain先生领导了Maxim制造供应链的许多方面的转型，使其更加灵活，敏捷和有弹性。Jain先生的其他经验包括担任英特尔技术开发和制造工厂的工厂经理，在那里他监督深亚微米逻辑和闪存技术的工艺技术开发和大批量制造。他持有the Indian Institute of Technology Delhi的化学工程学士学位，宾夕法尼亚州立大学（Penn State University）的化学工程硕士学位，以及斯坦福大学（Stanford University）的电气工程硕士学位。
- Vivek Jain joined the Company in February 2014 as Chairman of the Board and Chief Executive Officer. Mr. Jain served as CareFion Corporation's ("CareFion") President of Procedural Solutions from 2011 to February 2014. Mr. Jain served as President, Medical Technologies and Services of CareFion from 2009 until 2011. Mr. Jain served as the Executive Vice President Strategy and Corporate Development of Cardinal Health from 2007 until 2009. Mr. Jain served as Senior Vice President, Biness Development and M&A for the Philips Medical Systems biness of Koninklijke Philips Electronics N.V., an electronics company from 2006 to Augt 2007. Mr. Jain served as an investment banker at J.P. Morgan Securities, Inc., an investment banking firm, from 1994 to 2006. Mr. Jain's last position with J.P. Morgan was as Co Head of Global Healthcare Investment Banking from 2002 to 2006.